Bio-Rad(BIO) ZACKS·2025-02-14 20:01Core Insights - Bio-Rad Laboratories, Inc. reported fourth-quarter 2024 adjusted EPS of $2.90, missing the Zacks Consensus Estimate of $2.93 by 1.0% and reflecting a 6.4% decrease from the prior-year quarter [1][3] - The company’s full-year 2024 EPS was $10.31, down 12.5% year over year, and also slightly missed the Zacks Consensus Estimate by 0.2% [3] - Revenues for the fourth quarter were $667.5 million, missing estimates by 1.1% and decreasing 2.0% year over year [4] Financial Performance - The GAAP loss per share for the quarter was $25.57, compared to a GAAP EPS of $12.14 in the previous year [2] - Full-year 2024 revenues totaled $2.57 billion, a decrease of 3.9% from the prior year, but in line with the Zacks Consensus Estimate [4] - Cumulative net cash flow from operating activities was $455.2 million, up from $374.9 million year over year [9] Segment Analysis - Life Science segment sales were $275.0 million, down 5.5% year over year, primarily due to weakness in the biotech and biopharma markets [5] - Clinical Diagnostics segment net sales reached $392.5 million, reflecting a 0.9% year-over-year increase driven by demand for quality control and blood typing products [6] Margin and Expense Overview - Gross profit for the quarter declined 6.6% to $342 million, with gross margin contracting by 254 basis points to 51.2% [7] - Operating expenses increased by 4.6% year over year to $283.6 million, leading to an operating profit of $58.4 million, down 38.7% from the previous year [7] Financial Position - At the end of 2024, the company had cash and cash equivalents of $1.66 billion, up from $1.61 billion at the end of 2023, while total debt remained flat at $1.20 billion [8] Future Guidance - For full-year 2025, Bio-Rad anticipates non-GAAP currency-neutral revenue growth of 1.5-3.5%, with the Zacks Consensus Estimate for revenues at $2.65 billion, indicating a 3.1% increase from 2024 [11]